Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* T-cell lymphoma (excluding mycosis fungoides)~* WHO performance status 0-2~* measurable lesions~* acceptable hematological and biochemical parameters~* previously treated OR untreated but not suitable for standard therapy~Exclusion Criteria:~* pregnant~* HIV~* viral hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).